1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Epizyme, Inc.
  6. News
  7. Summary
    EPZM   US29428V1044


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. from RP Management LLC and others for approximately $250 million.

06/27/2022 EDT

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million on June 27, 2022. Ipsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per share plus a contingent value right of $1.00 per share. Each CVR will entitle its holder to deferred cash payments of $0.30 per CVR payable upon the first achievement of $250 million in aggregate net sales of Tazverik (excluding sales in Japan and Greater China) in any period of four consecutive quarters, by December 31, 2026 and $0.70 per CVR payable upon receipt of U.S. regulatory approval necessary for the commercial marketing and sale of the combination of Tazverik and R² (rituximab and lenalidomide) in second-line follicular lymphoma by January 1, 2028. The transaction will be fully financed by Ipsen's existing cash and lines of credit. As part of the transaction, Ipsen will also acquire Epizyme's first-in-class, oral SETD2 inhibitor development candidate, EZM0414, which was granted FDA Fast Track status and is currently under evaluation in a recently initiated Phase I/Ib trial in adult patients with relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma, as well as a portfolio of preclinical programs focusing on epigenetic targets. If the Merger Agreement is terminated under certain circumstances specified in the Merger Agreement, Epizyme will be required to pay Ipsen a termination fee of $9,900,000. The closing of the tender offer will be subject to customary conditions, including the tender of shares representing at least one share more than 50% of Epizyme's outstanding shares, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Upon the successful completion of the tender offer, Ipsen would acquire all shares not acquired in the tender through a second-step merger for the same consideration as the tendering shareholders. The Board of Directors of Epizyme has unanimously recommended that the stockholders of Epizyme tender their shares in the tender offer and other conditions. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors. Royalty Pharma, Epizyme's largest stockholder with approximately 20.5% of Epizyme's total shares of common stock outstanding has entered into a support agreement with Ipsen pursuant to which it has agreed to tender its shares in the tender offer. The Offer initially will remain open for 20 business days, subject to possible extension on the terms set forth in the Merger Agreement. Transaction is anticipated to close by the end of the third quarter of 2022. The offer is expected to expire on August 8, 2022. As of August 5, 2022, the expiration of the offer has been extended to August 11, 2022. As of August 9, 2022, the transaction is expected to close in third quarter of 2022. The acquisition of Epizyme will immediately provide incremental sales and will leverage the U.S. commercial infrastructure. Given the level of ongoing R&D expenses, the transaction is expected to be moderately dilutive on Ipsen's core operating income until the end of 2024. The dilutive impact on 2022 core operating margin will be limited, given the expected timing of the transaction. Barclays PLC (LSE:BARC) acted as financial advisor and Tony Chan, Daniel Lopez, Lynne T. Hirata, Michael Wiesner, David Schulman, Gargi Talukder, Shannon Yavorsky, John Narducci, Craig Falls, Danielle Mangogna, Jennifer Clarke-Smith, Matthew Rose, Kristin Petersen, Lars Mesenbrink, Harry Clark, Jeanine P. McGuinness, Ramon Galvan, Alex Talarides, Jared Mark, Virginia Ong, Alexis Smith, Jim Riley, Carrie Barclay, Deborah Abernathy and Marsha Mogilevich of Orrick, Herrington & Sutcliffe LLP acted as legal advisors to Ipsen Biopharmaceuticals, Inc. Jefferies Financial Group Inc. (NYSE:JEF) and MTS Health Partners, L.P. acted as financial advisors and Stuart M. Falber and Hal J. Leibowitz of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisors to Epizyme, Inc. MTS Securities, LLC provided an opinion to the Board of Directors of Epizyme regarding the fairness of the offer consideration to be received by the holders of Epizyme common stock in the transaction, subject to the qualifications and limitations set forth therein. Computershare Trust Company, National Association acted as Depositary and Paying Agent and Georgeson LLC acted as information agent to Ipsen.

© S&P Capital IQ 2022
All news about EPIZYME, INC.
08/15Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
08/14France's Ipsen Finalizes Purchase of US Biopharmaceutical Group Epizyme
08/12EPIZYME, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition ..
08/12Epizyme Announces Management Changes
08/12Epizyme, Inc. Appoints Grant Bogle as Chief Executive Officer
08/12EPIZYME, INC.(NASDAQGS : EPZM) dropped from S&P Global BMI Index
08/12EPIZYME, INC.(NASDAQGS : EPZM) dropped from S&P TMI Index
08/11EPIZYME, INC.(NASDAQGS : EPZM) dropped from NASDAQ Biotechnology Index
08/11Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. from RP Manag..
08/09EPIZYME : Reports Second Quarter 2022 Financial Results and Provides Business Update - For..
More news
Analyst Recommendations on EPIZYME, INC.
More recommendations
Financials (USD)
Sales 2022 47,5 M - -
Net income 2022 -179 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,32x
Yield 2022 -
Capitalization 247 M 247 M -
Capi. / Sales 2022 5,21x
Capi. / Sales 2023 2,91x
Nbr of Employees 250
Free-Float 76,2%
Duration : Period :
Epizyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPIZYME, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Grant C. Bogle President, Chief Executive Officer, CFO & Director
David M. Mott Chairman
Jeffery L. Kutok Chief Scientific Officer & Executive VP
Jerald Korn Chief Operating Officer
Carl Samuel Goldfischer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EPIZYME, INC.-41.20%247
WUXI APPTEC CO., LTD.-23.26%40 492
BIONTECH SE-36.97%39 486